The correlation and role analysis of SLC30A1 and SLC30A10 in cervical carcinoma

Background: SLC30 family genes, also known as ZnT family genes, can keep cellular zinc levels within a physiological range by exporting zinc to extracellular space or by isolating zinc in the specific regions of cytoplasm when cellular zinc concentrations are elevated in human cells. There are growing evidences that dysregulated expression of SLC30 family genes can potentially influence tumorigenesis. However, the expression and prognostic value of SLC30 family genes in cervical carcinoma are poorly characterized. Methods: In this study, we used many tools such as UALCAN, Kaplan-Meier Plotter, cBioPortal, LinkedOmics, FunRich, Metascape, GeneMANIA, Open targets and TISIDB to perform bioinformatics analysis of SLC30 family genes in cervical carcinoma. Results: We found that the expression of SLC30A1/7/10 was significantly higher in cervical carcinoma than that in normal matched tissues, while SLC30A2/8 mRNA levels were decreased compared to normal tissues. For tumor stages, SLC30A1, SLC30A7 and SLC30A10 groups significantly varied. And a high expression of SLC30A1, SLC30A6, SLC30A8 and SLC30A10 was associated with worse overall survival in cervical carcinoma patients. Besides, we found that SLC30A1/10 may have a potential regulatory role in immune infiltration in cervical carcinoma. In addition, the results showed that the high expression of SLC30A1 was resistant to 79 drugs or small molecules; Two drugs (Neopeltolide and Tozasertib) can inhibit the high expression of SLC30A10 in cancers. Conclusion: SLC30A1 and SLC30A10 can be recognized as potential diagnostic indicators and therapeutic targets in cervical carcinoma.

Automated summary

SLC30A1 and SLC30A10 can be considered as potential diagnostic indicators and therapeutic targets in cervical carcinoma based on the bioinformatics analysis. The expression of SLC30A1/7/10 is significantly higher in cervical carcinoma, while SLC30A2/8 mRNA levels are decreased. High expression of SLC30A1, SLC30A6, SLC30A8, and SLC30A10 is associated with worse overall survival in cervical carcinoma patients. In addition, SLC30A1/10 may have a potential regulatory role in immune infiltration in cervical carcinoma.